NCT05872438

Brief Summary

Screening for STIs in MSM is based on multisite samples: urine, anal and oral for PCR targeting C. trachomatis, N. gonorrhoeae, M. genitalium and T. vaginalis, whereas only vaginal self-sampling is recommended in women. Recent publications and observations suggest that a substantial number of STIs are under diagnosed with the current recommendations. The main objective of the study is to assess the number and percentage of additional C. trachomatis and N. gonorrhoeae infections diagnosed by a multiple sampling strategy in women, particularly when the vaginal sampling is negative The secondary objective will assess the acceptability of anal and oropharyngeal self-sampling relative to vaginal self-sampling in women.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,500

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Apr 2023

Geographic Reach
1 country

7 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 14, 2023

Completed
19 days until next milestone

First Submitted

Initial submission to the registry

May 3, 2023

Completed
21 days until next milestone

First Posted

Study publicly available on registry

May 24, 2023

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 19, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 19, 2024

Completed
Last Updated

November 18, 2024

Status Verified

November 1, 2024

Enrollment Period

1.4 years

First QC Date

May 3, 2023

Last Update Submit

November 15, 2024

Conditions

Keywords

Sexually Transmitted InfectionPCRC. trachomatisN. gonorrhoeaeScreening

Outcome Measures

Primary Outcomes (1)

  • Detectability of STIs in women on multisite samples

    Number and percentage percentage of additional STI diagnosed with the 3 sites sampling compared to the vaginal sampling alone

    Baseline

Secondary Outcomes (1)

  • Percentage of women accepting anal and oropharyngeal self-sampling

    Baseline

Study Arms (1)

Multisite sampling

OTHER

Vaginal, Oral and anal sampling for all participants

Diagnostic Test: Vaginal, Oral and anal sampling

Interventions

The patients will take the samples themselves from the 3 sites (vaginal, anal and oral self-sampling) using standard swabs (brand). The sample will immediately be placed in the transport medium in each of the 3 Sigma VCM tubes labeled by the patient, depending on the collection site. The study nurse will register the inclusion of patients, identify the tubes, collect information and send them to the local laboratory for the PCR to be performed.

Multisite sampling

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Women coming for STI screening at a Cegidd
  • Asymptomatic or not
  • Women aged at least 18 years
  • Having given her consent to participate

You may not qualify if:

  • Patient having received antibiotic treatment covering C.trachomatis and N.gonorrheae in the month preceding the screening
  • Patient under guardianship or curatorship
  • Patient under legal protection
  • Pregnant or breastfeeding woman

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (7)

CeGIDD

Orléans, 45000, France

Location

CHRU de POITIERS

Poitiers, 86021, France

Location

Centre Hospitalier de Cornouaille

Quimper, France

Location

CH de Saint Nazaire

Saint-Nazaire, France

Location

CHU de STRASBOURG

Strasbourg, 67000, France

Location

CHU de Tours

Tours, 37044, France

Location

Centre Hospitalier de Vierzon

Vierzon, France

Location

Related Publications (5)

  • Prazuck T, Lanotte P, Le Moal G, Hocqueloux L, Sunder S, Catroux M, Garcia M, Perfezou P, Gras G, Plouzeau C, Leveque N, Beby-Defaux A. Pooling Rectal, Pharyngeal, and Urine Samples to Detect Neisseria gonorrhoeae, Chlamydia trachomatis, and Mycoplasma genitalium Using Multiplex Polymerase Chain Reaction Is as Effective as Single-Site Testing for Men Who Have Sex With Men. Open Forum Infect Dis. 2022 Oct 31;9(10):ofac496. doi: 10.1093/ofid/ofac496. eCollection 2022 Oct.

    PMID: 36324326BACKGROUND
  • Verougstraete N, Verbeke V, De Canniere AS, Simons C, Padalko E, Coorevits L. To pool or not to pool? Screening of Chlamydia trachomatis and Neisseria gonorrhoeae in female sex workers: pooled versus single-site testing. Sex Transm Infect. 2020 Sep;96(6):417-421. doi: 10.1136/sextrans-2019-054357. Epub 2020 May 13.

    PMID: 32404400BACKGROUND
  • Lunny C, Taylor D, Hoang L, Wong T, Gilbert M, Lester R, Krajden M, Ogilvie G. Self-Collected versus Clinician-Collected Sampling for Chlamydia and Gonorrhea Screening: A Systemic Review and Meta-Analysis. PLoS One. 2015 Jul 13;10(7):e0132776. doi: 10.1371/journal.pone.0132776. eCollection 2015.

    PMID: 26168051BACKGROUND
  • Alexander S, Ison C, Parry J, Llewellyn C, Wayal S, Richardson D, Phillips A, Smith H, Fisher M; Brighton Home Sampling Kits Steering Group. Self-taken pharyngeal and rectal swabs are appropriate for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae in asymptomatic men who have sex with men. Sex Transm Infect. 2008 Nov;84(6):488-92. doi: 10.1136/sti.2008.031443.

    PMID: 19028953BACKGROUND
  • Wayal S, Llewellyn C, Smith H, Hankins M, Phillips A, Richardson D, Fisher M; Home Sampling Kit Project Steering Group. Self-sampling for oropharyngeal and rectal specimens to screen for sexually transmitted infections: acceptability among men who have sex with men. Sex Transm Infect. 2009 Feb;85(1):60-4. doi: 10.1136/sti.2008.032193. Epub 2008 Aug 15.

    PMID: 18708480BACKGROUND

Related Links

MeSH Terms

Conditions

Sexually Transmitted Diseases

Condition Hierarchy (Ancestors)

Communicable DiseasesInfectionsGenital DiseasesUrogenital DiseasesDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Julienne EFFA, Dr

    CHU d'Orléans

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Model Details: Comparison of screening for two hypothesis: How many and what percentage of additional STI are diagnosed with the 3 sites sampling compared to the vaginal sampling alone?
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 3, 2023

First Posted

May 24, 2023

Study Start

April 14, 2023

Primary Completion

September 19, 2024

Study Completion

September 19, 2024

Last Updated

November 18, 2024

Record last verified: 2024-11

Locations